Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Gene Therapy PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
NCT03861273Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2019
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 16
01
Overview
A Phase 3 trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Started Jul 2019; status: active, not recruiting.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03861273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861273.